# Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers

> **NCT02260050** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** WAL 801 CL dry syrup new formulation
- **DRUG:** WAL 801 CL dry syrup conventional formulation

## Key facts

- **NCT ID:** NCT02260050
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2004-07
- **Final completion:** —
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2014-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260050, "Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02260050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*